Title | Chelation therapy to treat atherosclerosis, particularly in diabetes: is it time to reconsider? |
Journal | Expert Review of Cardiovascular Therapy |
Authors | Ergui I, Lamas GA |
Year Published | 2016 |
Link to article |
Expert commentary
Chelation reduced adverse cardiovascular events in a post myocardial infarction (MI) population. Patients with diabetes demonstrated even greater benefit, with a number needed to treat of 6.5 patients to prevent a cardiac event over 5 years, with a 41% relative reduction in risk of a cardiac event (p = 0.0002). These results led to the revision of the ACC/AHA guideline recommendations for chelation therapy, changing its classification from class III to class IIb. TACT2, a replicative trial, will assess the effects of chelation therapy on cardiovascular outcomes in diabetic patients with a prior myocardial infarction. We are seeking participating sites for TACT2.